Skip to main content

Advertisement

Table 1 Summary of previously published case reports about the use of rFVIIa in patients with ventricular assist devices

From: Recombinant activated factor VII (Novo7®) in patients with ventricular assist devices: Case report and review of the current literature

  Flynn et al., [4] Kogan et al., [5] Potapov et al., [6] Zietkiewicz et al., [7]
Type of VAD LVAD RVAD BIVAD LVAD
Blood loss before rFVIIa 1500 mL/h Massive bleeding 1000 mL/h 1000 mL/h
Therapy before administration of rFVIIa 11 FFP 7 PC. PPSB* 15 FFP 16 PC. (20 units RBC) 56 FFP 4 PC. 2000 i.U. PPSB 28 μg desmopressine protamine* aprotinine* (30 units RBC) FFP* PC* tranexamic acid* (RBC)*
Laboratory values before administration of rFVIIa not reported INR: 2,86 PTT: > 120 sec. Fib.: 115 mg/dl PLT.: 78.000/μL INR: 1,39 PTT: 42,5 sec. Fib.: 212 mg/dl AT: 83% PLT.: 54.800/μL INR: 1,61 AT: 62% Fib.: 271 mg/dL PLTr.: 89.000/μL
Dose of rFVIIa 90 μg/kg 2 × 35 μg/kg 120 + 60 μg/kg 20 + 30 μg/kg
Blood loss after rFVIIa < 100 mL/h 0 < 100 mL/h < 15 mL/h
Laboratory values after administration of rFVIIa not reported INR: 1,3 PTT: 34 sec. Fib.: 127 mg/dL PLT.: 88.000/μl INR: 1,19 PTT: 47 sec. Fib.: 144 mg/dL AT: 52% PLT.: 75.700/μL INR: 0,89
Clinical course/outcome Discharged from hospital with permanent LVAD, listed for heart transplantation Recompensation, explantation of RVAD, discharged from hospital No thromboembolic complications. Outcome not reported. No thromboembolic complications. Lethal tension pneumothorax 7 days after implantation of VAD.
  1. *: Dosage not applicable